These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 15115394)

  • 1. Peptide-based inhibitors of the hepatitis C virus NS3 protease: structure-activity relationship at the C-terminal position.
    Rancourt J; Cameron DR; Gorys V; Lamarre D; Poirier M; Thibeault D; Llinàs-Brunet M
    J Med Chem; 2004 May; 47(10):2511-22. PubMed ID: 15115394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic approach to the optimization of substrate-based inhibitors of the hepatitis C virus NS3 protease: discovery of potent and specific tripeptide inhibitors.
    Llinàs-Brunet M; Bailey MD; Ghiro E; Gorys V; Halmos T; Poirier M; Rancourt J; Goudreau N
    J Med Chem; 2004 Dec; 47(26):6584-94. PubMed ID: 15588093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products.
    Ingallinella P; Altamura S; Bianchi E; Taliani M; Ingenito R; Cortese R; De Francesco R; Steinkühler C; Pessi A
    Biochemistry; 1998 Jun; 37(25):8906-14. PubMed ID: 9636032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanistic role of an NS4A peptide cofactor with the truncated NS3 protease of hepatitis C virus: elucidation of the NS4A stimulatory effect via kinetic analysis and inhibitor mapping.
    Landro JA; Raybuck SA; Luong YP; O'Malley ET; Harbeson SL; Morgenstern KA; Rao G; Livingston DJ
    Biochemistry; 1997 Aug; 36(31):9340-8. PubMed ID: 9235976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NMR structural characterization of peptide inhibitors bound to the Hepatitis C virus NS3 protease: design of a new P2 substituent.
    Goudreau N; Cameron DR; Bonneau P; Gorys V; Plouffe C; Poirier M; Lamarre D; Llinas-Brunet M
    J Med Chem; 2004 Jan; 47(1):123-32. PubMed ID: 14695826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel potent macrocyclic inhibitors of the hepatitis C virus NS3 protease: use of cyclopentane and cyclopentene P2-motifs.
    Bäck M; Johansson PO; Wångsell F; Thorstensson F; Kvarnström I; Ayesa S; Wähling H; Pelcman M; Jansson K; Lindström S; Wallberg H; Classon B; Rydergård C; Vrang L; Hamelink E; Hallberg A; Rosenquist S; Samuelsson B
    Bioorg Med Chem; 2007 Nov; 15(22):7184-202. PubMed ID: 17845856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The design and enzyme-bound crystal structure of indoline based peptidomimetic inhibitors of hepatitis C virus NS3 protease.
    Ontoria JM; Di Marco S; Conte I; Di Francesco ME; Gardelli C; Koch U; Matassa VG; Poma M; Steinkühler C; Volpari C; Harper S
    J Med Chem; 2004 Dec; 47(26):6443-6. PubMed ID: 15588076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles.
    Chen KX; Njoroge FG; Arasappan A; Venkatraman S; Vibulbhan B; Yang W; Parekh TN; Pichardo J; Prongay A; Cheng KC; Butkiewicz N; Yao N; Madison V; Girijavallabhan V
    J Med Chem; 2006 Feb; 49(3):995-1005. PubMed ID: 16451065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel azapeptide inhibitors of hepatitis C virus serine protease.
    Bailey MD; Halmos T; Goudreau N; Lescop E; Llinàs-Brunet M
    J Med Chem; 2004 Jul; 47(15):3788-99. PubMed ID: 15239657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphorous acid analogs of novel P2-P4 macrocycles as inhibitors of HCV-NS3 protease.
    Pompei M; Francesco ME; Koch U; Liverton NJ; Summa V
    Bioorg Med Chem Lett; 2009 May; 19(9):2574-8. PubMed ID: 19328685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-peptidic small-molecule inhibitors of the single-chain hepatitis C virus NS3 protease/NS4A cofactor complex discovered by structure-based NMR screening.
    Wyss DF; Arasappan A; Senior MM; Wang YS; Beyer BM; Njoroge FG; McCoy MA
    J Med Chem; 2004 May; 47(10):2486-98. PubMed ID: 15115392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of (1R,2S)-1-amino-2-vinylcyclopropanecarboxylic acid vinyl-ACCA) derivatives: key intermediates for the preparation of inhibitors of the hepatitis C virus NS3 protease.
    Beaulieu PL; Gillard J; Bailey MD; Boucher C; Duceppe JS; Simoneau B; Wang XJ; Zhang L; Grozinger K; Houpis I; Farina V; Heimroth H; Krueger T; Schnaubelt J
    J Org Chem; 2005 Jul; 70(15):5869-79. PubMed ID: 16018680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of the P1 side chain on the binding of optimized carboxylate and activated carbonyl inhibitors of the hepatitis C virus NS3 protease.
    Kawai SH; LaPlante SR; Llinàs-Brunet M; Hucke O
    Future Med Chem; 2010 Jul; 2(7):1073-81. PubMed ID: 21426157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent 7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid-based macrocyclic inhibitors of hepatitis C virus NS3 protease.
    Chen KX; Njoroge FG; Pichardo J; Prongay A; Butkiewicz N; Yao N; Madison V; Girijavallabhan V
    J Med Chem; 2006 Jan; 49(2):567-74. PubMed ID: 16420042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenylglycine as a novel P2 scaffold in hepatitis C virus NS3 protease inhibitors.
    Ortqvist P; Peterson SD; Kerblom E; Gossas T; Sabnis YA; Fransson R; Lindeberg G; Helena Danielson U; Karlén A; Sandström A
    Bioorg Med Chem; 2007 Feb; 15(3):1448-74. PubMed ID: 17113777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C virus NS3-4A serine protease inhibitors: SAR of P'2 moiety with improved potency.
    Arasappan A; Njoroge FG; Chan TY; Bennett F; Bogen SL; Chen K; Gu H; Hong L; Jao E; Liu YT; Lovey RG; Parekh T; Pike RE; Pinto P; Santhanam B; Venkatraman S; Vaccaro H; Wang H; Yang X; Zhu Z; Mckittrick B; Saksena AK; Girijavallabhan V; Pichardo J; Butkiewicz N; Ingram R; Malcolm B; Prongay A; Yao N; Marten B; Madison V; Kemp S; Levy O; Lim-Wilby M; Tamura S; Ganguly AK
    Bioorg Med Chem Lett; 2005 Oct; 15(19):4180-4. PubMed ID: 16087332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological activity of m-tyrosine-based 16- and 17-membered macrocyclic inhibitors of hepatitis C virus NS3 serine protease.
    Chen KX; Njoroge FG; Pichardo J; Prongay A; Butkiewicz N; Yao N; Madison V; Girijavallabhan V
    J Med Chem; 2005 Oct; 48(20):6229-35. PubMed ID: 16190750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of hepatitis C virus NS3.4A protease. Part 3: P2 proline variants.
    Perni RB; Farmer LJ; Cottrell KM; Court JJ; Courtney LF; Deininger DD; Gates CA; Harbeson SL; Kim JL; Lin C; Lin K; Luong YP; Maxwell JP; Murcko MA; Pitlik J; Rao BG; Schairer WC; Tung RD; Van Drie JH; Wilson K; Thomson JA
    Bioorg Med Chem Lett; 2004 Apr; 14(8):1939-42. PubMed ID: 15050632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents.
    Lampa A; Ehrenberg AE; Gustafsson SS; Vema A; Kerblom E; Lindeberg G; Karlén A; Danielson UH; Sandström A
    Bioorg Med Chem; 2010 Jul; 18(14):5413-24. PubMed ID: 20541424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the P2 and P3 ligand binding features for hepatitis C virus NS3 protease using some 3D QSAR techniques.
    Wei HY; Lu CS; Lin TH
    J Mol Graph Model; 2008 Apr; 26(7):1131-44. PubMed ID: 18024210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.